Alcon Inc.

Approximately 80-85% of Alcon's revenue derives from implants, surgical disposables, and replacement contact lenses reordered with each procedure or replacement cycle. Revenue grew every year from FY2020 through FY2025, including through COVID-related surgical volume declines, demonstrating durable de-facto recurring character despite the absence of formal contractual arrangements.

Alcon reports two structurally distinct segments: Surgical ($5.8B in FY2025) and Vision Care ($4.5B in FY2025), serving different clinical workflows and customer types. Within Surgical, sub-diversification across implantables, consumables, and equipment reduces single-line exposure, though the two-segment structure caps overall diversification credit.

Alcon operates in more than 140 countries, with the US representing the single largest market at approximately 40-45% of total revenue and international markets spanning Europe, Asia Pacific, and Latin America. Management has highlighted competitive pressure in the US IOL market and accelerating growth in international markets, indicating a moderately balanced geographic footprint.

Revenue has grown from $7.1B in FY2019 to $10.3B in FY2025, but capital-intensive contact lens manufacturing and heavy R&D investment for successive surgical platforms constrain operating leverage. Core operating margins were approximately 160 basis points below the prior-year level in Q4 2025, reflecting the ongoing investment cycle required to sustain a competitive product pipeline.

Surgical consumables are mission-critical per procedure, and contact lens replacement creates high patient retention as clinicians prescribe specific products and patients habitually reorder. Both revenue streams are procedurally driven or habit-forming, with strong repeat-purchase dynamics and limited exposure to spot-market or purely discretionary demand.